Best Practices for Probiotic Clinical Research · Clinical Research Regulations – Dietary...
Transcript of Best Practices for Probiotic Clinical Research · Clinical Research Regulations – Dietary...
Best Practices for Probiotic
Clinical Research
Clinical Research Regulations – Dietary Supplements/NHPs
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
US – Dietary Supplement� Code of Federal Regulations (CFR)
� Part 50 – PROTECTION OF HUMAN SUBJECTS
� Part 56—INSTITUTIONAL REVIEW BOARDS
Both are applicable to dietary supplements as stated in the scope detailed in the CFR.
FTC case law defines “competent and reliable” scientific evidence in only general terms as: “tests, analyses, research, studies, or other evidence based on the expertise of professionals in the relevant area, that have been conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results.”
Canada – Natural Health Products� Regulation: Part 4 of the Natural Health Products
Regulations (NHP Regulations) June 18, 2003 (SOR/2003-196)
� Section 74: “Every sponsor shall ensure that a clinical trial is conducted in accordance with good clinical practices”
� Guidance: Clinical Trials for Natural Health Products Guidance Document
Summary of the Principles of ICH
1. Conduct trials according to GCP
2. Weigh risks vs. benefits
3. Subjects wellbeing exceed scientific needs
4. Have adequate information to justify trial
5. Write a sound protocol
6. Receive IRB approval
7. Use qualified physicians
8. Use qualified, trained (education and experience) staff
9. Obtain informed consent
10. Record all information appropriately
11. Confidentiality & data protection
12. Handle IP appropriately (GMP, use per protocol)
13. Quality Assurance
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
ICH Ancillary Guidance Documents
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Why GCP? Regulatory Acceptability
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Clinical Trial Design & Infrastructure
IND/Biologic Clinical
Investigations
(Global Application)
Natural Health Products
(Canada) / Global
Application
ICH E6 (R2)
(Global)
NHPR / ICH
(Canadian Regulation)
Unregulated
?
Dietary Supplements
(US Application)
Validation
Documentation
Inspection
Readiness
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Claims Substantiation
Validation
Documentation
Risk
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Regulatory Insight
• Deficiencies in studies submitted to substantiate claims to EFSA (adapted from Guidance on Statistical Reporting EFSA Journal 2014; 12(2):3908)
• Inappropriate patient population or inclusion/exclusion criteria
• No or lack of control group
• Inappropriate statistical powering of study
• Insufficient method of randomization
• Inappropriate statistical tests and reporting of results
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Best Practices – Study Participants (Target Population)
• Define the target population• General population?
• Subset of population?
• Jurisdiction of interest?
Study Design Challenges:
• Use of enriched populations
• Combining product efficacy with microbiome analysis / genetics to identify potential responders -> reduce sample size and potential success rate
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Best Practices – Study Product / Control and Blinding
• Choice of Control Groups
• Placebo?
• Active Comparator?
• Standard of Care?
• Ensure:
� All groups get the same number, types of product,
and dose regimen
� If capsule/tablet, ensure all have similar
characteristics (size, weight, color, no unique
markings, etc.)
� If food (e.g. yogurt) choose an acidified milk with
no active cultures, or heat-treat the yogurt
� The protocol should include the justification for
choice of control product and measures to ensure
blinding
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Best Practices – Blinding (Example 1 – Dose Finding Trial)
Groups
Group 1 Group 2 Group 3 Group 4
Products Low-Dose Mid-Dose High-Dose Placebo
Active
Capsules1 2 3 0
Placebo
Capsules2 1 0 3
Total Capsules
/ day3 3 3 3
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Best Practices – Blinding (Example 2 –Comparator Trial)
Group
Group 1
(Test Product
(capsule))
Group 2
(Comparator
Product
(yogurt))
Group 3
(Placebo)
Pro
du
ct
Active Capsule �
Active Yogurt�
Heat-Treated Yogurt � �
Placebo Capsule � �
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Best Practices – Blinding (Product Packaging)
Labels:
� Must meet local and
federal requirements
� Should prevent any
accidental unblinding
� Should not differ except
by randomization
number
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Randomization
• Eliminates the selection bias
• Balances the groups with respect to many known and unknown confounding or prognostic variables
• Forms the basis for statistical tests
• Generating randomization tables needs to be reproducible
• Generation of a randomization schedule usually includes obtaining the random numbers and assigning random numbers to each subject.
• Best practice is to use computer programming to do randomization such as SAS
• Common Types of Randomization in Clinical Research• Simple randomization
• Block randomization
• Stratified randomization
• Covariate adaptive randomization
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Sample Size
• Sample size should reflect:– Effect size (Mean change over and above placebo)
– Estimate of variability regarding the change (SD)
– Level of power (80%, 90%)
– Estimate attrition rate (withdrawals)
– Statistical significance (P value, e.g. 0.05 (5% the result is due to chance))
• Estimates should be made based on prior research on specific formulation– If information is unavailable, study may be considered
proof of concept study, may be suitable for guidance of future studies
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Determining Effect Size and Dose
• Pilot study in target population, multiple doses, placebo-controlled
• Results provided from study design:
• Determination of effective dose
• Effect size
• Estimate of variability in response
• Measure of efficacy
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Statistical Analysis Plan
• Should be available prior to data analysis (latest before database lock) (not ad hoc)
• Contains analyses and population definition including inclusion/exclusion criteria as well as subgroup analysis and their relation to the study objectives
• Potential issues should be anticipated, and response to manage such incidents documented
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Product Characteristics - Stability
• Live organisms require specific handling and storage to maintain efficacy
• Stability testing is a risk mitigation strategy for clinical trials
• Regulatory bodies (such as Health Canada) require stability data to be
submitted to support probiotic clinical studies
– At minimum, to demonstrate stability of the product for study duration
– Conduct real-time studies with the clinical investigation, allowing substitution of a new
lot during trial if stability of product starts to drift
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Product Characteristics - Stability
Complementing Real-time stability:
• Ship using a validated shipping container and include a digital data logger
• Include extra bottles (QC samples) in the shipment for testing viability at
defined periods during the trial (on receipt at CRO/site, specific time
points during study, on last subject last visit)
• Collect and test random subject returns to provide confidence that study
product was help appropriate by study subjects
• Depending on product-specific requirements, it may be necessary to
provide the CRO / site(s) with coolers for transport if the probiotic is
sensitive to heat exposure.
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Product Characteristics – Duration of Intervention
The duration of intervention should be based on:
• The time it takes for the product to have an effect
• Duration should be long enough for transient effects to stabilize
• Consideration must also be given to the outcome of interest
• If crossover design, how long do the products effects last? Will the
markers of interest return to similar baseline levels, and if so, how long
does this take?
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Sample Characteristics – Stability
• Defined in Protocol or ancillary documents such as a Laboratory Manual
• Preparation and storage of samples should be based on validated methodology
• Points of consideration:– Sample collection – temperature, time between sampling and processing and/or
storage, are buffers/preservatives needed?
– Blood collection – tube type (EDTA, K2EDTA, Sodium citrate, sodium fluoride, heparin)?
– Transfer tubes – is there binding to the plastics, is sterility needed?
– Processing – conditions for rotating or vortexing, centrifugation, transfer at room temperature / duration before storage
– Storage – room temperature, refrigerated, frozen (-20°C or -80°C)
– Stability – how long can samples be stored (stability assays on sample storage) for and analysis still valid? Freeze thaw cycles?
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Confounding Factors
• Inclusion and exclusion criteria must be carefully and explicitly defined, considering factors such as:– Activity levels
– Dietary habits
– Concomitant medications (including supplements)
– Blood and urine markers
• Broad enough to include those effected by the claim, but exclude those who may experienced increased risk of safety associated with:– Product use
– Interactions with other drugs
– Other confounding factors which may influence the study
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Endpoint Selection
• Formulated in correspondence with the claim, considering acceptable biomarkers and validated questionnaires
• Clearly defined and measured in clinical study to prevent misestimating sample size or failure of hypothesis
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Endpoint Selection
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Importance of Data Management
• Data management is like filing, do it well and you can find
answers quickly
• Increasingly important as regulators and industry continue to
push toward
• Real world data
• Wearable technology
• Virtual trials
• Novel trial designs
• Increased vigilance of safety data
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Data Management
MD trial
MD trial
MD trial
Academic
trial
Academic
trial
Academic
trial
Sponsor
trial
Sponsor
trial
• How can the Sponsor
use all these data?
• Are there common themes emerging?
• Are there any safety issues?
• Do the Sponsor controlled trials support
findings in other non-Sponsor Initiated
Studies?
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Data Management
Global Data Management Plan:
Standardize data elements in line with current and emerging standards
(clinical and non-clinical)
Aggregate Data by 1) Species or 2) Strain
Subset Data by Indication Subset Data by Indication
• Assess probiotic-drug interactions
• Assess probiotic-disease interactions
• Assess weight on evidence
• Assess total subject exposure
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Data Management
Data standards for coding
- MedDRA, WhoDD
Data standards for research
(e.g. CDISC, CDASH)
Safety Profile by
Strain and by
Indication
Investigator
Brochure
ADR Reporting
RCTs, etc.
ICH RegionCTA, PLA, IND
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Data Management
Data standards for coding
- MedDRA, WhoDD
Data standards for
research
Safety Profile by
Strain and by
Indication
Investigator
Brochure
ADR Reporting
RCTs, etc.
ICH RegionCTA, PLA, IND
www.nutrasource.ca © Nutrasource Pharmaceutical and Nutraceutical Services 2019
Nutrasource Pharmaceutical and Nutraceutical Services
120 Research Lane, Suite 203Guelph, Ontario, Canada N1G 0B4
www.nutrasource.ca
Joshua Baisley, B.Sc.Vice President, Clinical Design & Delivery